Should Medable's decentralized clinical trial platform prioritize ease of use for patients or more comprehensive data collection for researchers?

Introduction

The trade-off between prioritizing ease of use for patients or more comprehensive data collection for researchers in Medable's decentralized clinical trial platform presents a critical decision point. This scenario encapsulates the tension between user experience and data richness in clinical research. I'll analyze this trade-off by examining stakeholder needs, potential impacts, and strategic considerations to arrive at a balanced recommendation.

Step 1

Clarifying Questions (3 minutes)

• Based on the current market trends, I'm thinking patient-centricity might be a key differentiator. Could you share more about our competitive landscape and how this aligns with our strategic priorities?

Why it matters: Helps position our solution in the market context Expected answer: Patient-centricity is a growing trend, but data quality remains crucial Impact on approach: Would influence the balance between user experience and data comprehensiveness

• Considering the diverse stakeholders in clinical trials, I'm curious about our primary revenue streams. Are we primarily serving pharmaceutical companies, research institutions, or do we have a more diverse client base?

Why it matters: Identifies key stakeholders and their priorities Expected answer: Mix of pharma and research institutions, with growing interest from smaller biotech firms Impact on approach: Would help tailor the solution to meet the needs of our most valuable clients

• Given the critical nature of clinical data, I'm wondering about our current data quality metrics. How does our platform currently perform in terms of data completeness and accuracy?

Why it matters: Establishes a baseline for data quality considerations Expected answer: Generally high data quality, but room for improvement in certain areas Impact on approach: Would inform the extent to which we can prioritize ease of use without compromising data integrity

• Thinking about the technical aspects, I'm curious about our platform's current flexibility. How easily can we implement modular features that cater to both patient ease of use and comprehensive data collection?

Why it matters: Assesses technical feasibility of a balanced approach Expected answer: Platform is modular but requires significant development for major changes Impact on approach: Would influence the timeline and resource allocation for implementing changes

• Considering the potential impact on ongoing trials, I'm interested in our current user base. What's the scale of active trials and participants on our platform?

Why it matters: Helps gauge the scope and potential risks of implementing changes Expected answer: Significant number of active trials with varying scales of participation Impact on approach: Would inform the rollout strategy and potential phasing of any changes